Protagen and ZAP Partner with Kangdi Antibody Biotech and Bejing Proteome Research Centre to Develop Antibodies
News May 16, 2007
Protagen AG has entered into an international collaboration to develop antibodies against liver proteins.
Protagen announced it’s partnership with the Centre for Applied Proteomics (ZAP), Dortmund, Schunde Kangdi Antibody Biotech, Foshan, China and the Beijing Proteome Research Centre (Beijing PRC) at the interna¬tional symposium on High Performance Proteomics in Dortmund.
The involvement of Protagen in the collaboration will be to develop tailor-made protein biochips that can be used to analyze quantitative antibody binding profiles, as well as any off-target activities of antibody candidates.
UNIchip® products of Protagen are versatile research tools that enable antibody development by identifying the most specific antibody candidates at an early stage of development.
ZAP will use UNIchip® to assess around 200 monoclonal antibodies, generated by Schunde Kangdi Antibody Biotech and Beijing PRC. The results will be used to identify those antibodies that are most promising for future develop¬ment as research tools or therapeutics or for use in diagnostic kits. The industrial partners are sharing the worldwide commercialization rights for the antibodies analyzed.
Professor Helmut E. Meyer, Head of the Human Brain Proteome Project and Director of ZAP and Professor Fuchu He, Head of the Human Liver Proteome Project and president of the Beijing PRC, will share the scientific leadership on the project. The two institutes have already worked together for a number of years within the framework of the Human Proteome Organization (HUPO).
Professor Meyer said: “As the proteome is so much more complex than the genome, it is more costly to research. It is therefore useful to work with a number of partners to draw on a wide range of experience and pool resources. We are looking forward to working with Protagen and tapping into the company’s exten¬sive experience in protein research to help us achieve our goals.”
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Study Indicates 75% of Human Genome is Non-functionalNews
An evolutionary biologist at the University of Houston has published new calculations that indicate no more than 25 percent of the human genome is functional.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018